Medicare’s 2026 rules are largely set, bringing a tougher shopping season than last year. Part D completes the second step of its redesign, traditional Medicare begins a targeted prior-authorization test in 6 states, and Medicare Advantage enters 2026 with higher average payments. Several large insurers are cutting plans, trimming “extras,” and raising some out-of-pocket limits, making careful plan review essential.
- Part D: what’s locked in for 2026. CMS set the defined-standard Part D deductible at $615 and the annual out-of-pocket cap at $2,100. After you hit that threshold, your cost-sharing for covered drugs drops to $0 for the rest of the year. Vaccines recommended by ACIP remain at $0 under Part D, and insulin stays capped at $35 per month (or less, depending on negotiated or plan prices). CMS also finalized how plan, manufacturer, and Medicare liabilities shift once negotiated “maximum fair prices” begin for selected drugs, and created a selected drug subsidy to keep plan payments aligned with those negotiated amounts. (CMS)
- Premium smoothing continues. For 2026, CMS announced a base Part D beneficiary premium of $38.99 and the second year of its Premium Stabilization Demonstration: a uniform $10 reduction to the base, a higher cap on year-over-year premium increases (up to $50), and removal of 2025’s narrower risk corridors. Actual premiums still vary by plan and market, but the levers above are meant to reduce whiplash as plans adjust to the redesigned benefit. (CMS)
- Part B outlook. Independent projections point to a meaningful Part B premium increase—into the $206.50 range monthly—with the Part B deductible and IRMAA brackets also stepping up. These are projections, not final amounts; the official numbers typically post later in the year. (Investopedia)
- Medicare Advantage payments—and new guardrails. CMS’s 2026 rate announcement projects an average 5.06% increase in federal payments to MA plans versus 2025, reflecting a higher effective growth rate and the last leg of a technical adjustment phase-in. At the same time, the Contract Year 2026 final rule tightens several consumer protections: limits on when plans can reopen previously approved inpatient stays (essentially only for clear error or fraud), clarified appeals rights (including for concurrent care decisions), and a codified list of non-allowable supplemental items to keep SSBCI benefits tied to health goals. (CMS)
- What changed in the market—and why it matters when you shop. Insurers are reacting to higher-than-expected medical costs and regulatory shifts by pruning products and prioritizing margins rather than pure membership growth. Expect more plan exits, benefit trims, and higher out-of-pocket caps in many MA plans, though not universally. Net effect: expect tougher comparisons and more surprises if you auto-renew without reading this year’s notices. (Wall Street Journal)
- Fewer plans and higher pharmacy costs in Part D. The number of standalone Part D drug plans will drop sharply again in 2026—down to 360 offerings, from 464 in 2025 and 709 in 2024. Many of the remaining plans are shifting cost share from flat copays to coinsurance, and drug deductibles are rising across a swath of products. Run your actual medication list on Medicare.gov’s Plan Finder and review each plan’s formulary and tier/coinsurance rules before enrolling; a plan that was optimal in 2025 may not be in 2026. (Wall Street Journal)
- Medicare Advantage plan design is narrowing. Big carriers are scaling back some PPOs and leaning more on HMOs, which generally restrict out-of-network coverage. A growing number of hospitals are also leaving MA networks, making it essential to confirm that your doctors and preferred facilities are in-network for 2026. Do not rely solely on online directories; call providers to verify. If broad, unrestricted access is your priority, Original Medicare plus a Medigap policy remains the most flexible path—but outside your initial eligibility window, Medigap can be medically underwritten and costlier or unavailable depending on your state. (Wall Street Journal)
- Out-of-pocket caps are moving. Many large-insurer MA plans are lifting their maximum out-of-pocket (MOOP) limits for 2026, though a few are lowering them. The MOOP is the ceiling for your in-year spending on covered Part A/B services; with higher caps, a serious illness or hospitalization could cost more than last year. Check the MOOP in your Annual Notice of Change (ANOC) and compare it across any plans you’re considering in the Summary of Benefits and Evidence of Coverage. (Wall Street Journal)
- Expect leaner “extras.” Some carriers are cutting back on supplemental perks that had become common enrollment sweeteners—store credits for healthy foods or OTC items, fitness trackers, and broad flex allowances. Others are preserving more of those benefits, but the overall trend is toward tighter, health-oriented definitions and lower dollar amounts. If a particular allowance mattered to you in 2025, confirm its 2026 status line by line. (Wall Street Journal)
- A note on broker incentives. Carriers are also reducing commissions on certain products—especially standalone Part D plans and some PPOs—which means agents have less financial reason to surface them. That doesn’t mean you can’t buy them; it does mean you should check all your options directly on Medicare.gov and consider free, unbiased help from your State Health Insurance Assistance Program (SHIP) or the Medicare Rights Center. (Wall Street Journal)
- Targeted prior authorization test in traditional Medicare. Beginning January 1, 2026, the WISeR model (Wasteful and Inappropriate Service Reduction) will pilot in AZ, NJ, OH, OK, TX, and WA. For a defined set of outpatient services historically prone to overuse or fraud, Medicare will apply prior authorization or post-service review. Decisions must be made by licensed clinicians; coverage rules do not change. The test runs six performance years and evaluates whether better front-end review can curb spending without harming access. (Federal Register)
Bottom line for 2026 enrollment. The rules are clearer—$615 Part D deductible, $2,100 drug OOP cap, $0 vaccines, $35 insulin, new payment and consumer-protection standards—while the market is tougher, with fewer plans, more HMOs, higher MOOPs in many MA products, leaner perks, and shifting drug-benefit math. Read your ANOC, verify your doctors and hospitals, price your exact medications on Plan Finder, and compare the MOOP and pharmacy cost structure across finalists before you enroll. For many enrollees, a careful re-shop—not an auto-renew—will be the safest path this year.
Clarity-Spot is for informational purposes only. It is not intended to be a substitute for professional advice. Perform your own research before making any decisions.